Bayer is successfully executing on an ambitious growth strategy Five pivotal approvals worldwide in 2025 underscore a landmark year of strategic execution Bayer will...
In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade and Bayer partner together to help raise awareness about an available treatment option for moderate to severe hot flashes...
Not intended for UK Media Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis...
Not intended for UK Media Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer...
Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President...
Bayer Crop Science Canada is excited to announce the launch of Sivanto® Energy, a groundbreaking foliar insecticide designed to deliver swift, reliable pest control with extended protection. Formulated...
BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome...
Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics...
Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately...
Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control...